Drugs / Fibrin Sealant Grifols
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00684047 | Feb 2008 → Mar 2014 | bleeding disorder, vascular-type | Grifols, S.A. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03461406 | Jan 2019 → Apr 2022 | — | Grifols, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01754480 | Mar 2013 → Dec 2015 | — | Grifols, S.A. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fibrin Sealant Grifols | “Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)” NCT00684047 ↗ |
| Known as | FS Grifols | “Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries” NCT01754480 ↗ |
| Modality | Protein / enzyme biologic | “human plasma-derived fibrin sealant Grifols (FS Grifols)” NCT00684047 ↗ |
| Route | Topical | “applied topically to the target bleeding site” NCT01754480 ↗ |